Bebtelovimab: The FDA-approved Monoclonal Antibody for Treating Patients with Mild-to-Moderate COVID-19

Pouya  Safarzadeh Kozani; Mehdi Sheikhi; Narges Baharifar; Setareh Dashti Shokoohi; Sara Sheikhi; Seyed Mohamad Javad Mirarefin; Pooria Safarzadeh Kozani; Abdolkarim Sheikhi

doi:10.5812/tms-130706

Bebtelovimab: The FDA-approved Monoclonal Antibody for Treating Patients with Mild-to-Moderate COVID-19

authors:

Pouya Safarzadeh Kozani ¹ , Mehdi Sheikhi ² , Narges Baharifar ³ , Setareh Dashti Shokoohi ⁴ , Sara Sheikhi ⁵ , Seyed Mohamad Javad Mirarefin ⁶ , Pooria Safarzadeh Kozani ⁷ , Abdolkarim Sheikhi ^{3
, *}

1 Department of Medical Biotechnology, Faculty of Paramedicine, Guilan University of Medical Sciences, Rasht, Iran

2 Faculty of Medicine, Kazeroon Branch, Islamic Azad University, Kazeroon, Iran

3 Department of Immunology, School of Medicine, Dezful University of Medical Sciences, Dezful, Iran

4 Department of Biology, Yadegar-e-Imam Khomeini (RAH) Shahre Rey Branch, Islamic Azad University, Tehran, Iran

5 School of Nursing & Midwifery, Iran University of Medical Sciences, Tehran, Iran

6 Department of Immunology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran

7 Department of Medical Biotechnology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran

Trends in Medical Sciences: Vol.2, issue 3; e130706

published online: August 20, 2022

article type: Discussion

received: August 10, 2022

accepted: August 11, 2022

DOI: https://doi.org/10.5812/tms-130706

how to cite: Safarzadeh Kozani P , Sheikhi M, Baharifar N, Dashti Shokoohi S, Sheikhi S, et al. Bebtelovimab: The FDA-approved Monoclonal Antibody for Treating Patients with Mild-to-Moderate COVID-19. J Adv Immunopharmacol. 2022;2(3):e130706. https://doi.org/10.5812/tms-130706.

Keywords

COVID-19 FDA Monoclonal antibody Treatment Bebtelovimab

Footnotes

Authors' Contribution: MS, NB, SDS, SS, and SMJM contributed to writing, and PSK, PSK, and AS contributed to writing and revising the manuscript.
Conflict of Interests: The authors declare no conflict of interest.
Ethical Approval: IR.SEMUMS.REC.1399.174. Link: ethics.research.ac.ir/EthicsProposalView.php?id=151308.
Funding/Support: This article was financially supported by Dezful University of Medical Sciences, Dezful, Iran.

References

1.
Interim Clinical Guidance for Management of Patients with Confirmed Coronavirus Disease (COVID-19). CDC; 2022, [cited 2/26/2022]. Available from: https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-guidance-management-patients.html..
2.
Madelon N. Omicron-Specific Cytotoxic T-Cell Responses After a Third Dose of mRNA COVID-19 Vaccine Among Patients With Multiple Sclerosis Treated With Ocrelizumab. JAMA Neurol. 2022. https://doi.org/10.1101/2021.12.20.21268128.
3.
Doshi P, Godlee F, Abbasi K. Covid-19 vaccines and treatments: we must have raw data, now. BMJ. 2022;376:o102. [PubMed ID: 35045956]. https://doi.org/10.1136/bmj.o102.
4.
Mathieu E, Ritchie H, Ortiz-Ospina E, Roser M, Hasell J, Appel C, et al. Author Correction: A global database of COVID-19 vaccinations. Nat Hum Behav. 2021;5(7):947-53. [PubMed ID: 34140660]. [PubMed Central ID: PMC8210736]. https://doi.org/10.1038/s41562-021-01160-2.
5.
Coronavirus (COVID-19) Update: FDA Authorizes New Monoclonal Antibody for Treatment of COVID-19 that Retains Activity Against Omicron Variant. FDA; 2022, [cited 2/26/2022]. Available from: https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-new-monoclonal-antibody-treatment-covid-19-retains.
6.
Westendorf K, Zentelis S, Wang L, Foster D, Vaillancourt P, Wiggin M, et al. LY-CoV1404 (bebtelovimab) potently neutralizes SARS-CoV-2 variants. Cell Rep. 2022;39(7):110812. [PubMed ID: 35568025]. [PubMed Central ID: PMC9035363]. https://doi.org/10.1016/j.celrep.2022.110812.

comments